Indaptus Therapeutics (INDP) Price & Analysis

Compare

530 Followers

INDP Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.56 - $66.61

Previous CloseN/A

Volume47.54K

Average Volume (3M)476.85K

Market Cap

$6.36M

Enterprise Value$2.43M

Total Cash (Recent Filing)$3.89M

Total Debt (Recent Filing)$59.51K

Price to Earnings (P/E)―

Beta2.08

Next Earnings

Aug 18, 2025

EPS Estimate

-9.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-8.96

Shares Outstanding572,658

10 Day Avg. Volume1,359,996

30 Day Avg. Volume476,845

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)0.49

Price to Sales (P/S)0.00

P/FCF Ratio-0.90

Enterprise Value/Market Cap0.38

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.04

Forecast

1Y Price Target

$2.00

Price Target Upside-82.00% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Indaptus Therapeutics News

PremiumThe Fly

Indaptus Therapeutics announces additional sale of $3.4M in private placement

7d ago

INDP

PremiumThe Fly

Indaptus Therapeutics Inc trading resumes

11d ago

INDP

PremiumThe Fly

Indaptus Therapeutics Inc trading halted, volatility trading pause

11d ago

INDP

PremiumThe Fly

Indaptus Therapeutics Inc trading halted, news pending

11d ago

INDP

PremiumThe Fly

Indaptus Therapeutics board approves 1-for-28 reverse stock split

13d ago

INDP

PremiumMarket News

3 Penny Stocks to Watch Now, 6/24/25

14d ago

INDO

PremiumThe Fly

Indaptus Therapeutics announces sale of $2.3M of convertible notes, warrants

25d ago

INDP

PremiumCompany Announcements

Indaptus Therapeutics Raises $5.7M for R&D Initiatives

7d ago

INDP

See All INDP News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressIndaptus Therapeutics, Inc. has started dosing the first patient in a study combining Decoy with Tislelizumab for solid tumors, marking an important step in the study's progress.

Therapeutic PotentialThe combination of Decoy20 with tislelizumab aims to treat tumors that are non-responsive or have stopped responding to other treatments, providing new potential options for patients.

Bears Say

Capital RequirementsThe company needs to raise additional capital in the near-term, which could pose financial risks.

Financial PerformanceIndaptus reported a net loss of ($4.5M) and ended the period with $3.9M in cash on the balance sheet, highlighting financial challenges.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

10.13% Insiders

2.09% Mutual Funds

1.32% Other Institutional Investors

84.86% Public Companies and Individual Investors

Detailed Ownership Overview >

INDP FAQ

What was Indaptus Therapeutics’s price range in the past 12 months?

Indaptus Therapeutics lowest stock price was $7.56 and its highest was $66.61 in the past 12 months.

What is Indaptus Therapeutics’s market cap?

Indaptus Therapeutics’s market cap is $6.36M.

When is Indaptus Therapeutics’s upcoming earnings report date?

Indaptus Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is in 41 days.

How were Indaptus Therapeutics’s earnings last quarter?

Indaptus Therapeutics released its earnings results on May 14, 2025. The company reported -$8.96 earnings per share for the quarter, missing the consensus estimate of -$5.04 by -$3.92.

Is Indaptus Therapeutics overvalued?

According to Wall Street analysts Indaptus Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Indaptus Therapeutics pay dividends?

Indaptus Therapeutics does not currently pay dividends.

What is Indaptus Therapeutics’s EPS estimate?

Indaptus Therapeutics’s EPS estimate is -9.24.

How many shares outstanding does Indaptus Therapeutics have?

Indaptus Therapeutics has 572,658 shares outstanding.

What happened to Indaptus Therapeutics’s price movement after its last earnings report?

Indaptus Therapeutics reported an EPS of -$8.96 in its last earnings report, missing expectations of -$5.04. Following the earnings report the stock price went down -3.734%.

Which hedge fund is a major shareholder of Indaptus Therapeutics?

Currently, no hedge funds are holding shares in INDP

Company Description

Indaptus Therapeutics

Indaptus Therapeutics (INDP) is a biotechnology company focused on developing innovative therapies for the treatment of serious diseases. The company specializes in leveraging its proprietary technologies to create novel drug candidates aimed at addressing unmet medical needs. Operating within the pharmaceutical and biotechnology sectors, Indaptus Therapeutics is dedicated to advancing its pipeline of therapeutic products through rigorous research and development processes.

INDP Stock 12 Month Forecast

Average Price Target

$2.00

▼(-82.00%Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","42":"$42","83":"$83","21.5":"$21.5","62.5":"$62.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,21.5,42,62.5,83],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Nov<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.53,8.95076923076923,8.37153846153846,7.792307692307691,7.2130769230769225,6.633846153846154,6.054615384615384,5.475384615384614,4.896153846153846,4.316923076923077,3.737692307692307,3.1584615384615375,2.5792307692307688,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.53,8.95076923076923,8.37153846153846,7.792307692307691,7.2130769230769225,6.633846153846154,6.054615384615384,5.475384615384614,4.896153846153846,4.316923076923077,3.737692307692307,3.1584615384615375,2.5792307692307688,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.53,8.95076923076923,8.37153846153846,7.792307692307691,7.2130769230769225,6.633846153846154,6.054615384615384,5.475384615384614,4.896153846153846,4.316923076923077,3.737692307692307,3.1584615384615375,2.5792307692307688,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.8,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.32,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.52,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.4,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.73,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.36,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.04,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >